Shiono Satoshi, Harada Mayumi, Abiko Masami, Sato Toru, Takanashi Imi
Dept. of Thoracic Surgery,Yamagata Prefectural Central Hospital.
Gan To Kagaku Ryoho. 2014 Jun;41(6):757-9.
We present the case of an 84-year-old man with lumbago due to bone metastases from lung cancer that recurred three years after surgery. The patient received carboplatin-paclitaxel combination as first-line chemotherapy for the treatment of lung cancer, and palliative radiotherapy for the treatment of bone metastases. Gemcitabine was administered as second-line chemotherapy. However, disease progression was observed after three years, and he developed pulmonary metastases. The general condition of the patient worsened, and tegafur-uracil chemotherapy was initiated. Zoledronic acid was also administered. The tegafur-uracil treatment resulted in the disappearance of pulmonary metastases, and a stabilization of the bone metastases. Disease progression was observed after 6 years with a recurrence of pulmonary metastases; however, this did not have a negative impact on the patient's quality of life. Although slow progression may be inherent to lung cancers, it is also possible that the tegafur-uracil and zoledronic acid combination might have contributed to the patient's improved performance.
我们报告了一例84岁男性患者,因肺癌骨转移导致腰痛,术后三年复发。患者接受卡铂-紫杉醇联合方案作为一线化疗治疗肺癌,并接受姑息性放疗治疗骨转移。吉西他滨作为二线化疗药物。然而,三年后观察到疾病进展,且出现了肺转移。患者的一般状况恶化,遂开始使用替加氟-尿嘧啶化疗。同时也给予了唑来膦酸。替加氟-尿嘧啶治疗使肺转移灶消失,骨转移灶稳定。6年后观察到疾病进展,出现了肺转移复发;然而,这并未对患者的生活质量产生负面影响。尽管肺癌可能固有缓慢进展的特性,但替加氟-尿嘧啶与唑来膦酸的联合使用也可能对患者状况的改善起到了作用。